<DOC>
	<DOCNO>NCT00481013</DOCNO>
	<brief_summary>The primary objective proposal determine whether oral VPA effective treat SMA adult patient .</brief_summary>
	<brief_title>Valproic Acid Ambulant Adults With Spinal Muscular Atrophy</brief_title>
	<detailed_description>Participation study entail six visit seven eight blood draw 13 month . Each visit entail stay two day one night General Clinical Research Center ( GCRC ) . Subjects live within drive distance allow participate study without overnight stay two consecutive outpatient visit . All subject evaluate two screen visit 2-4 week apart determine eligibility participation . Eligible subject randomize receive VPA placebo first six month . At six-month visit , patient evaluate crossed regimen .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Ambulatory adult SMA 3 age 1860 . The diagnosis SMA must document homozygous deletion SMN1 gene standard genetic test disorder . Patients must able walk thirty foot without assistance ( i.e . cane , walker ) . 2 . Interest participate ability meet study requirement . 3 . Women child bear age require birth control abstain participate study . 1 . Nonambulatory type 3 adult type 2 adult . 2 . Patients comorbid condition preclude travel , test study medication . 3 . Patients participate treatment trial SMA 3 month prior trial , plan enrol treatment trial duration trial . 4 . Patients , investigator 's opinion , mentally legally incapacitate providing inform consent study , otherwise unable meet study requirement cooperate reliably study procedure , especially strength test . 5 . Patients need noninvasive ventilatory support ( e.g . BiPAP ) &gt; 12 hours/day 6 . Transaminases , amylase lipase &gt; 3.0 x normal value , WBC &lt; 3.0 neutropenia &lt; 1.0 , platelet count &lt; 100 K , hematocrit &lt; 30 persist 30 day period 7 . Use medication supplement interfere VPA metabolism increase potential risk medication , hypothesize beneficial effect SMA animal model human neuromuscular disorder within 3 month study enrollment . These agent include riluzole , creatine , butyrate derivative , growth hormone , anabolic steroid , daily albuterol use , anticonvulsant , HDAC inhibitor . 8 . Women pregnant intend become pregnant participate research study breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>Adult</keyword>
</DOC>